COST-EFFECTIVENESS OF ROSIGLITAZONE COMBINATION THERAPY FOR THE TREATMENT OF TYPE 2 DIABETES IN THE CZECH REPUBLIC

被引：0
|
作者：
Dolezal, T. [1 ]
Skoupa, J. [2 ]
Taylor, M. J. [3 ]
Whitehead, S. [3 ]
Rausova, V [4 ]
Pavlikova, P. [4 ]
机构：
[1] Charles Univ Prague, Prague, Czech Republic
[2] Pharma Projects, Prague, Czech Republic
[3] Univ York, York YO10 5DD, N Yorkshire, England
[4] GlaxoSmithKline Inc, Prague, Czech Republic
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66674-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A504 / A504
页数：1
相关论文
共 50 条
  • [31] Shoulder Joint Arthroplasty Cost-Effectiveness in the Czech Republic
    Jerabkova, Silvie
    Fulin, Petr
    Vacek, Jakub
    Holubova, Hana
    [J]. 2015 E-HEALTH AND BIOENGINEERING CONFERENCE (EHB), 2015,
  • [32] Cost-Effectiveness Analysis of University Hospitals in the Czech Republic
    Gajdogova, Eva
    [J]. THEORETICAL AND PRACTICAL ASPECTS OF PUBLIC FINANCE 2016, 2016, : 140 - 145
  • [33] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Manrique, H.
    Solorzano, J.
    Gagliardino, J. J.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
  • [34] COST-EFFECTIVENESS ANALYSIS OF 4% FLUOROURACIL FOR THE TREATMENT OF ACTINIC KERATOSIS IN THE CZECH REPUBLIC
    Blazkova, T.
    Mlcoch, T.
    Ornstova, E.
    Sevec, M.
    Dolezal, R.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S142 - S142
  • [35] COST-EFFECTIVENESS OF ROMIPLOSTIM FOR THE TREATMENT OF PATIENTS WITH EARLY IMMUNE THROMBOCYTOPENIA IN THE CZECH REPUBLIC
    van Beurden-Tan, C.
    Kucera, Z.
    Pasztor, B.
    Vesela, S.
    Cervinek, L.
    Konirova, E.
    Kozak, T.
    Majer, I. M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S372 - S373
  • [36] Combination therapy for Type 2 diabetes: repaglinide plus rosiglitazone
    Raskin, P
    McGill, J
    Saad, MF
    Cappleman, JM
    Kaye, W
    Khutoryansky, N
    Hale, PM
    [J]. DIABETIC MEDICINE, 2004, 21 (04) : 329 - 335
  • [37] The cost-effectiveness of adding rosiglitazone versus sulfonlurea to metformin in a US obese type 2 diabetes population
    Richter, A
    Thieda, P
    Bagust, A
    Perry, A
    [J]. DIABETES, 2003, 52 : A524 - A524
  • [38] Rosiglitazone plus metformin: combination therapy for type 2 diabetes
    Del Prato, S
    Volpe, L
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) : 1411 - 1422
  • [39] Cost-Effectiveness of DPP-4 Inhibitor and SGLT2 Inhibitor Combination Therapy for Type 2 Diabetes
    Pawaskar, Manjiri
    Bilir, S. Pinar
    Kowal, Stacey
    Gonzalez, Claudio
    Rajpathak, Swapnil
    Davies, Glenn
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2019, 25 (05): : 231 - +
  • [40] THE COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN COMBINATION WITH INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SPAIN
    Sanchez-Covisa, J.
    Capel, M.
    Schmidt, R.
    Charokopou, M.
    Verheggen, B. G.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A350 - A350
12345